MedTrace Logo

The Efficacy of Automated Feedback After Internet-based Depression Screening

NCT04633096 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1178

Last updated 2023-09-21

No results posted yet for this study

Summary

The DISCOVER randomized controlled trial is designed to evaluate the effect of automated feedback after internet-based depression screening in individuals with undetected depression. A total of 1076 individuals reporting elevated levels of depression (PHQ-9 score ≥ 10 points) will be randomized into three groups to either receive a) no feedback (control group), b) standardised or c) tailored feedback on their depression screening results.The primary hypothesis is that feedback reduces depression severity six months after screening compared to no feedback. The secondary hypothesis is that tailored feedback is more efficacious as compared to standard feedback.

Conditions

Interventions

BEHAVIORAL

tailored feedback of depression screening results

The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment. The information is tailored to the participant's individual symptom profile, illness perceptions and preferences.

BEHAVIORAL

standardized feedback of depression screening results

The feedback for the participant contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.

Sponsors & Collaborators

  • German Research Foundation

    collaborator OTHER

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Sebastian Kohlmann, PhD · University Medical Center Hamburg-Eppendorf, Department of Psychosomatic Medicine and Psychotherapy

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04633096 on ClinicalTrials.gov